NFL Biosciences in the lower end of the range





Photo credit © Reuters

(Boursier.com) – NFL Biosciences has finally raised 5 ME as part of its IPO. The funds raised will allow NFL Biosciences to accelerate its development through the completion of the Phase II / III study of its drug candidate NFL-101, the recruitment of talents to strengthen the organization, the initiation of NFL-programs. 201 and NFL-301, for treatment of cannabis addiction and reduction of alcohol consumption.

The Board of Directors of NFL Biosciences, meeting today, therefore noted the partial exercise of the extension clause and set the price of the Open Price Offer at 3.80 euros per share, i.e. the bottom of the range. indicative which ranged from 3.4 to 4.6 Euros. Beginning of negotiations on July 5.


© 2021, Boursier.com



Laisser un commentaire